Recombinant Human FAAH Protein，His

Fatty acid amide hydrolase (FAAH) is an enzyme primarily responsible for the catabolism of endogenous signaling lipids, particularly the fatty acid amides, including anandamide. An understanding of FAAH’s biochemical and structural properties is critical due to its significant role in various physiological processes, such as pain modulation, inflammation, and neuroprotection. Dysregulation of FAAH activity has been linked to several disorders, including anxiety, depression, and inflammatory diseases, making it an attractive target for therapeutic intervention. The research on recombinant FAAH proteins focuses on elucidating their structure-function relationships, enzymatic mechanisms, and interactions with lipid substrates and inhibitors. By producing recombinant FAAH in various expression systems, researchers aim to obtain a sufficient quantity of purified enzyme for in-depth biochemical assays and structural studies. Furthermore, studies involving FAAH knockout models and pharmacological inhibitors have underscored the enzyme's potential as a drug target, promoting interest in developing FAAH inhibitors for clinical applications. Overall, the comprehensive understanding of FAAH through recombinant protein studies could pave the way for novel therapeutic strategies aimed at modulating endocannabinoid signaling pathways.